In this third Catenion webinar, Dr. Ilkin Ozer, consultant at Catenion, presents microbiome-based therapeutics as an emerging drug class with great potential for biopharma, based on public information as of January 2022.
- The field: the microbiome is the collection of organisms, mostly bacteria and viruses, that colonize the human body. On average there are 1.3 bacterial cells for every human cell, and every individual has a unique microbiome signature. Over 5,000 species and 300 million genes have been identified and about 85% of the microbial genome has been mapped. The microbiome plays a role in obesity and oncology, but undersampling and the unknown function of many sequenced genes remain gaps. Milestones include the transfer of host phenotypes through microbiota transplantation (2006), the NIH microbiome project (2008) and the first positive phase 3 results for microbiome therapeutics (2020).
- Key players: bacterial replacement therapy (SERES Therapeutics, Vedanta Biosciences, Finch Therapeutics, Rebiotix, acquired by Ferring in 2018, Enterome, Evelo Biosciences, Second Genome and Microbiotica), metabolic therapy (Axial Biotherapeutics and Kaleido Biosciences), phage therapy (Locus Biosciences and BiomX) and precision microbiome therapy (Eligo Bioscience and Artizan Biosciences).
- Clinical activity: the key players focus on C. difficile infections, with promising phase 2 and 3 data on reducing recurrence. As of January 2022, 78 trials were ongoing, mostly in phase 1 and 2, mainly in gastrointestinal and infectious diseases, followed by oncology. Failures also occur: SERES’s phase 2 study in ulcerative colitis showed no difference in clinical remission.
- Deals: after the hype of 2016, deal activity plateaued following failed phase 2 trials, and 2020 was the peak, mostly in capital raisings. Janssen has the most collaborations among big pharma, followed by Nestle Health Science and Takeda, while AbbVie (Allergan) and AstraZeneca have terminated some of theirs. SERES’s deal with Nestle Health Science was worth 525 million dollars.
- Metabolites and phages: Catenion believes metabolites are a more suitable target for diagnostics and treatment than the microbes themselves, because they respond rapidly to physiological changes, cross barriers more freely and are more conserved between individuals (unrelated individuals share 82% of metabolic pathways but only 43% of bacterial species). Bacteriophages are selective, which makes one-size-fits-all solutions difficult, so personalized phage therapies could be the future against antibacterial resistance. No fecal microbiota transplant product has been approved by the FDA, and in 2019 the agency warned about the risks after a patient died from a multi-drug-resistant infection.
Conclusion: Catenion believes the field is still in its infancy and that, in the long run, a focus on metabolites is likely necessary to fully leverage the scientific potential of this class of therapeutics.



